主页 > 医学动态 >
【medical-news】2008 ASCO报道之四：肿瘤药合用并不
In the years before targeted biotech drugs stormed the cancer scene, progress came in small increments, as doctors slowly worked out which combinations of chemo medicines worked best for which patients.
Now that there are several targeted biotech drugs on the market, researchers are starting to test whether two targeted drugs are better than one. The afternoon session at the American Society of Clinical Oncology brought some bad news on that front.
In a study of more than 755 patients with advanced colorectal cancer, adding Imclone’s Erbitux to Genetech’s Avastin actually shortened the time it took for disease to progress, on average. Even patients who had a genetic profile favorable to Erbitux treatment showed no benefit by adding the drug to Avastin.
Yet both drugs have been shown to improve outcomes when given singly to these patients.
“It shows you can’t throw things into a pot and assume they’ll work,” Robert Mayer, a colorectal cancer specialist at Dana-Farber Cancer Institute, told the Health Blog this afternoon. Mayer himself is working on a separate, similar study.
An earlier trial showed that adding Amgen’s Vectibix to Avastin in colorectal cancer patients did more harm than good. Still, there are plenty of studies in progress that are looking at combinations of targeted drugs.
Some are combining Genentech’s Herceptin and GlaxoSmithKline’s Tykerb in breast cancer patients — (see here and here). Here’s one that looks at Pfizer’s Sutent and AstraZeneca’s Iressa in kidney cancer. There are lots of others, with just about any targeted drug or tumor type you can think of.
It’s too early to say if any of the combos will work. But Mayer, for one, is hopeful that benefits will emerge: “Why are we doing this otherwise?”
http://blogs.wsj.com/health/2008/05/31/are-two-targeted-cancer-drugs-better-than-one/
screen.width-333)this.width=screen.width-333" width=200 height=133 title="Click to view full cookies_art_200_20080531193826.jpg (200 X 133)" border=0 align=absmiddle> 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Are Two Targeted Cancer Drugs Better Than One?
两种靶向抗癌药物比一种好吗？
In the years before targeted biotech drugs stormed the cancer scene, progress came in small increments, as doctors slowly worked out which combinations of chemo medicines worked best for which patients.
在靶向生物技术药物席卷抗癌市场之前，进步很小，因为医生为各类病人找到对应最佳化疗药物制品的速度很慢。
Now that there are several targeted biotech drugs on the market, researchers are starting to test whether two targeted drugs are better than one. The afternoon session at the American Society of Clinical Oncology brought some bad news on that front.
既然市场上有很多靶向生物技术药物，那么研究者正开始试验两个靶向药物是否会比一个更好些。美国临床肿瘤协会下午的会议带来了一些关于这个前沿的坏消息。
In a study of more than 755 patients with advanced colorectal cancer, adding Imclone’s Erbitux to Genetech’s Avastin actually shortened the time it took for disease to progress, on average. Even patients who had a genetic profile favorable to Erbitux treatment showed no benefit by adding the drug to Avastin.
在对超过755名晚期结直肠癌患者的研究中，平均来看，在Genetech公司的Avastin中添加Imclone公司的Erbitus实际上却缩短了疾病进展的时间。甚至根据有些病人的遗传概貌应用Erbitux治疗更合适，在将其添加至Avastin后也没显示出益处。
Yet both drugs have been shown to improve outcomes when given singly to these patients.
然而两种药物分别单独给予这些病人时都显示了较好的效果。
“It shows you can’t throw things into a pot and assume they’ll work,” Robert Mayer, a colorectal cancer specialist at Dana-Farber Cancer Institute, told the Health Blog this afternoon. Mayer himself is working on a separate, similar study.
今天下午Dana-Farber癌症研究所的结直肠癌专家Robert Mayer告诉健康博客: “这表明你不能把所有东西都扔进一个罐子里并且认为他们都将有效。”Mayer本人在做一个独立的，类似的研究。
An earlier trial showed that adding Amgen’s Vectibix to Avastin in colorectal cancer patients did more harm than good. Still, there are plenty of studies in progress that are looking at combinations of targeted drugs.
一个先前的临床试验显示将Amgen公司的Vectibix添加进Avastion对结直肠癌的病人有更大的害处而不是益处。但是仍然有很多靶向药物制品研究取得进展。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-18 17:14
医学,生命科学网